Proliferation and AKT activity biomarker analyses after Capivasertib (AZD5363) treatment of patients with ER+ invasive breast cancer (STAKT)

John F. R. Robertson (Lead / Corresponding author), Robert E. Coleman, Kwok-Leung Cheung, Abigail Evans, Chris Holcombe, Anthony Skene, Daniel Rea, Samreen Ahmed, Ali Jahan, Kieran Horgan, Petra Rauchhaus, Roberta Littleford, Sy Amy Cheung, Marie Cullberg, Elza C. de Bruin, Loumpiana Koulai, Justin P. O. Lindemann, Martin Pass, Paul Rugman, Gaia SchiavonRahul Deb, Pauline Finlay, Andrew Foxley, Julia M. W. Gee

Research output: Contribution to journal › Article › peer-review

18 Citations (Scopus)
59 Downloads (Pure)

Fingerprint

Dive into the research topics of 'Proliferation and AKT activity biomarker analyses after Capivasertib (AZD5363) treatment of patients with ER+ invasive breast cancer (STAKT)'. Together they form a unique fingerprint.

Medicine & Life Sciences